Biopolymer manufacturing expertise from Corbion delivers crucial capability and capacity to the commercialization of MedinCell's BEPO® technology, helping to make possible the unique benefits of a new long-acting, injectable product based on novel excipients.

The collaboration between joint venture partners Corbion and MedinCell officially bore fruit recently when MedinCell announced the approval by the U.S. Food & Drug Administration of an extended-release injectable suspension of risperidone used for the treatment of schizophrenia, representing the first approved product based on their BEPO technology1.

"This approval by the FDA shines a light on what Corbion brings to the table when we collaborate with our partners and validates our ability to enable partners to develop and ultimately gain product approval for innovative products based on the use of novel excipients," said Menno Lammers, VP Biomaterials at Corbion. "And in this case, our deep understanding of biomedical polymer manufacturing and our manufacturing footprint in Europe and the U.S. make it possible for us to support MedinCell's licensees with a secure supply of polymers, from early formulation research, throughout product development, and ultimately commercial launch."

As the global leader in resorbable polymers for drug delivery and medical devices, Corbion entered into a 50/50 joint venture – CM Biomaterials – with MedinCell in 2015. The JV was formed for the supply of polyethylene glycol- (PEG) and polylactide-based (PLA) copolymers in the field of controlled release drug delivery to MedinCell partners who license the BEPO technology. Under terms of the JV, manufacturing of the GMP-grade polymers takes place in Corbion medical biomaterials plants in the United States and the Netherlands.

BEPO® is a trademark of MedinCell

1 https://www.medincell.com/en/2023/04/29/teva-and-medincell-announce-fda-approval-of-uzedy-risperidone-extended-release-injectable-suspension-a-long-acting-subcutaneous-atypical-antipsychotic-injection-for-the-treatment-of-schiz/

Attachment

20230905 Press release FDA approval MedinCell final
ga naar
https://ml-eu.globenewswire.com/Resource/Download/88b840ee-7f39-4a32-a503-587c96842c9e


Transacties in aandelen Corbion. 2023
d.d. prijs 17.30.00 uur omzet aantal transacties idem na 17.35.00 uur en later.
15 mei. EUR 29,28 17.527 188 EUR 29,22 26.960 277 17.35.05
16 mei EUR 29,28 24.512 326 EUR 29,28 34.713 413 17.35.22
17 mei EUR 28,52 -----------------EUR 28,52 42.109 553 17.35.15
18 mei EUR 28,84 26.135 272 EUR 28.78 36.188 356 17.35.15
19 mei EUR 28,24 68.527 496 EUR 28,28 79.482 582 17.35.25

D.D. 15 mei 2023 om 18.28 uur Corbion
CENTRAL ORDER BOOK
# SHARES BID PRICE ASK PRICE SHARES #
1 1,000 29.14 29.80 900 1
1 10 28.70 30.00 600 1
1 100 28.48 30.28 300 1
1 1,000 28.30 30.48 100 1
1 10 28.00 30.58 35 1
1 50 27.68 30.70 17 1
3 400 27.50 30.86 200 1
1 18 27.44 31.00 500 4
1 93 27.20 31.06 88 1
1 40 27.08 31.10 50 1
-------2,721 -----------------2,790
12. ---------- Total ------------------13
Zo sluiten de systemen op elkaar af, voor de volgende dag de start van de laddersystemen. Dagelijkse kost!!!


Transacties in aandelen Corbion. 2023
d.d. prijs 17.30.00 uur omzet aantal transacties idem na 17.35.00 uur en later.
22 mei EUR 27,70. 35.906. 421. EUR 27.76. 55.366. 517 17.35.08
23 mei EUR 27,60 72.754 864 EUR 27.56 77.754 866 17.35.27
24 mei EUR 27,10 24.051 328 EUR 27,10 44.034 381 17.35.08
25 mei EUR 26,84 13.987 261 EUR 26,88 31.520 347 17.35.07
26 mei EUR 26,64 27.977 376 EUR 26,62 45.137 448 17.35.07

D.D. 26 mei 2023
CENTRAL ORDER BOOK Corbion
# SHARES BID PRICE ASK PRICE SHARES #
4 301 26.80 26.86 160 3
2 154 26.78 26.88 147 3
6 3,110 26.76 26.90 731 5
3 441 26.74 26.92 2,062 4
5 1,037 26.72 26.94 476 4
6 1,373 26.70 26.96 851 4
2 342 26.68 26.98 747 2
7 2,673 26.66 27.00 756 3
4 2,982 26.64 27.02 750 2
4 1,185 26.62 27.04 267 1
------13,598 ---------------6,947
43 -----------Total --------------------31
Vol. 8.003 aantal transacties 107 en Price EUR 26,88 , vrijwel de gehele tijdsduur meer vraag dan aanbod en steeds onder de slotprijs van gisteren. Op sociale media, eerst moet Corbion bij de EUR 25 zijn.
De LP 'ers doen hun reguliere werk niet volgens afspraak, t.w. zorgen voor een ordentelijke prijsvorming.